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http://dx.doi.org/10.1016/j.kjms.201Abstract A premature infant is a baby born before 37 weeks of gestation. Rickets is a bone
disease characterized by growth retardation due to the expansion of the hypertrophic chon-
drocyte layer of the growth plate and a failure to mineralize bone. Consequently, the bone
is soft and permits marked bending and distortion. Although the incidence of rickets in preterm
infants is lower due to improvements in health care and nutrition, there are still infants at high
risk for this disease. However, few reports are available regarding the treatment of rickets in
premature infants. Furthermore, published case studies on experiences with using calcitriol as
a potential therapeutic for rickets in premature infants are very rare. Herein, we describe the
detection of rickets in premature infants and our experience with calcitriol treatment in two
premature infants. We recommended the use of oral calcitriol at a dose of 0.03e0.125 mg/kg/
day, in addition to an appropriate formula that provides an adequate amount of calcium and
phosphate intake. One patient was prescribed calcitriol for 40 days and the other for 37 days.
The two infants gradually recovered and were discharged without any obvious side effects. It is
recommended that alkaline phosphatase levels be monitored within 1 month after birth in
premature infants with a birth weight of <1000 g. Infants presenting with high alkaline phos-
phatase levels are candidates for a long bone survey.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.of Pharmacy, Sin-Lau Hospital, Number 57, Section 1, Dongmen Road, East District, Tainan City 701,
yahoo.com.tw (H.-Y. Chen).
vier Taiwan LLC. All rights reserved.
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Bone is composed of osteoid, a protein matrix, and
a mineral phase that primarily consists of calcium and
phosphate, and is mostly in the form of hydroxyapatite.
Rickets is a disease of growing bone that occurs in children
only before epiphyseal fusion due to unmineralized matrix
at the growth plates, and leads to a variety of bone
deformities [1]. Mineralization is decreased at the level of
the growth plates and results in the expansion of growth
plate cartilage and osteoid, and thereby a thickening of the
growth plates. Thus, the circumference of the growth
plates and metaphysis is increased. This increase in bone
width at the location of the growth plates results in some
clinical manifestations. Specifically, patients may have
widened wrists and ankles, and there is a general softening
of the bones that causes them to bend easily when sub-
jected to forces, such as during weight bearing or muscle
pulling actions [1].
Although rickets has been largely corrected via public
health measures, which provided children with adequate
vitamin D, it remains a persistent problem in developed
countries [2]. In fact, rickets has not been completely
eradicated in industrialized countries, such as Canada and
UK. In Canada, the overall annual incidence rate of rickets
is roughly 2.9 cases per 100,000 children younger than 18
years [3]. In England, one study revealed that the overall
incidence of rickets was 7.5 per 100,000 children less than 5
years old, 38 per 100,000 children with a South Asian ethnic
origin, and 95 per 100,000 children with a black, African or
African-Caribbean ethnic origin. Interestingly, only one
child with a white ethnic origin was reported, giving an
incidence of 0.4 per 100,000 [4]. From 1995 to 2005, the
average incidence of nutritional rickets in children aged
0e14.9 and 0e2.9 years was 2.9 and 5.8 per 100,000 per
year, respectively [5]. Furthermore, osteopenia and rickets
are especially common among extremely low birth weight
infants (i.e., birth weight <1000 g). However, treatment
strategies for rickets with calcitriol in premature infants
have not been well established in Taiwan, as well as
worldwide [6]. Hence, more research in treating rickets in
premature infants with calcitriol is warranted.
Case presentations
Case 1
A male infant from a G3P2A1 mother was delivered by
emergency caesarean section at a gestational age of 25
weeks due to a low fetal heart rate (i.e., less than
80 beats/min). One dose of betamethasone was admin-
istered before delivery to facilitate lung maturation. His
birth weight was 830 g, head circumference was 23 cm,
chest circumference was 19.5 cm, and birth length was
37 cm. His Apgar score was 5 points at 1 minute to 6
points at 5 minutes after birth. After the caesarean
section, the infant was intubated and sent to the pedi-
atric intensive care unit. His mother had negative tests
for hepatitis B surface antigen, e antigen, and human
immunodeficiency virus (AIDS). The initial physical
examination revealed the following: body temperature,35.1C; heart rate, 160 beats/min; respiratory rate, 49
breaths/min; blood pressure, 65/19 mmHg (normal for
newborns <5 days old is 65e75/41e48 mmHg), and he
could move his limbs freely. Biochemical tests revealed
low serum calcium levels of 8.0 mg/L (normal level is
8.4e10.2 mg/dL), phosphorus levels of 6.1 mg/dL
(normal level is 4.5e7.5 mg/dL). On the 40th day, his
alkaline phosphatase (ALP) was 478 units (u)/L (normal
level is <400 u/L) (Table 1) [7]. On the 82nd day, the ALP
value increased to 1640 u/L. Rickets was suspected, and
vitamin D levels were analyzed via a radioactive immu-
noassay on the 87th day of hospitalization. The results
from the 25-hydroxy vitamin D3 (25OH Vit D3) test
demonstrated a normal 25OH Vit D3 level of 10.7 ng/mL
(normal level is 5.3e27.7 ng/mL), and a high 1,25OH Vit
D3 level of 82.1 pg/mL (normal level is 15.9e55.6 pg/
mL). On the 110th day, the serum bilirubin concentration
was higher (i.e., 12.1 mg/dL) than the normal range.
Thus, we administered 25 mg ursodesoxycholic acid
twice daily. On the 115th day, a long bone survey
demonstrated a fracture of the right humerus and heal-
ing of the right radius (Fig. 1). Additionally, his left femur
showed a rough edge (Fig. 2). Rickets was diagnosed
based on the following: (1) the long bones were relatively
empty and dark in the radiograph; (2) the left edge of the
thigh bone appeared to be rough; (3) the right humerus
was broken; and (4) normal liver function was present.
We suggested calcitriol as the first line of therapy instead
of alfacalcidol. The rationale for choosing calcitriol was
primarily because premature infants have immature liver
function and may have trouble converting alfacalcidol
into 1,25-dihydroxycholecalciferol. Calcitriol therapy
was initiated on the 115th day, and the daily dose was
0.03e0.125 mg/kg/day. The patient was discharged on
the 154th day when ALP levels decreased from 1821 u/L
(i.e., peak ALP) to 673 u/L (36.9% of the peak ALP). The
duration of calcitriol treatment was for 40 days.Case 2
A male infant from a G2P2A0 mother was delivered via
a natural and spontaneous delivery at a gestational age of
25 weeks. His birth weight and body length were 875 g and
37 cm, respectively. His Apgar score was 5 points at 1
minute to 7 points at 5 minutes after birth. The initial
physical examination revealed the following: body
temperature, 36.4C; heart rate, 134 beats/min; respira-
tory rate, 42 breaths/min; blood pressure 66/19 mmHg; he
also had poor activity and respiratory distress on the day of
admission. Biochemical tests revealed glutamic oxaloacetic
transaminase levels of 25 u/L (25e75 u/L) and glutamic
pyruvate transaminase (GPT) levels of 7 u/L (10e40 u/L),
and the total bilirubin level was 6.2 mg/dL (2e10 mg/dL)
(Table 2). On the 56th day, his ALP level was 1463 u/L. Thus,
0.0625 mg/kg/day of calcitriol was given until the 100th day,
and the dose was eventually titrated up to 0.125 mg/kg/
day. His ALP level was gradually reduced from 1463 u/L
(i.e., peak ALP) to 478 u/L (32.6% of the peak ALP). Neither
hypercalcemia nor hyperphosphatemia presented during
the calcitriol treatment. The patient was discharged on the
139th day, as he did not present with any side effects of
Table 1 Laboratory data in case 1.
Hospital
day
ALP
(85e400 u/L)
GOT
(18e74 u/L)
GPT
(8e78 u/L)
g-GT
(2e30 IU/L)
T-bilirubin
(0e1.5 mg/dL)
Ca
(8.8e11.2 mg/dL)
P
(3.8e6.7 mg/dL)
Ca P
Product
(mg/dL)2
Day 1 6.2
Day 40 478 10.1 3.75 37.87
Day 82 1640
Day 87 484 59 34
Day 96 817 214 68
Day 110 1134 208 54 207 12.1 8 5.3 42.4
Day 115 1821 531 130 229 13 9.2 5.1 46.9
Day 118 1420 125 79 239 11.6
Day 122 781 99 45 365
Day 126 887 185 67 561 9.8 5.0 49
Day 131 933 244 93 433
Day 136 976 147 69 258 9.7 5.3 51.41
Day 150 673 72 33 73 10.2 6.0 61.2
ALPZ alkaline phosphatase; CaZ calcium; GOTZ glutamic oxaloacetic transaminase; GPTZ glutamic pyruvate transaminase; g-
GTZ gamma-glutamyl transpeptidase; PZ phosphate.
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therapy was 37 days.
Discussion
Serum ALP activity has been traditionally used to screen for
metabolic bone disease in preterm infants. However, it wasFigure 1. Radiograph of right humerus fracture (arrow) and
radius.suggested that there is no significant difference in peak ALP
activity in infants that are diagnosed with rickets via radi-
ography versus those with osteopenia and no rickets. In
clinical practice, the diagnosis of rickets generally remains
dependent on clinical suspicion, and biochemical peak ALP
activity data with a radiograph verifying the findings [6].
The recommended dose of calcitriol for treating rickets
in premature infants is not well established. Additionally,
the treatment duration with calcitriol also remains to be
determined for premature infants. In one case report, a 6-
week treatment course with calcitriol at a dose of 0.25 mg
three times a day (0.3 mg/kg/day) showed that ALP levels
decreased from 4450 to 2270 u/L (i.e., ALP was reduced by
51%) [8]. In our two cases, treatment with calcitriol once
daily lowered ALP levels by 36.9% and 32.7% of peak ALP,
respectively. Both patients recovered gradually without
hypercalcemia or hyperphosphatemia. Serum calcium times
phosphorus product did not exceed 65 mg2/dL2 (see Tables
1 and 2) [9]. Thus, these findings suggest that there is
a possibility that a lower dose of calcitriol (i.e., 0.125 mg/
kg/day) is not inferior to a higher dose of calcitrol (i.e.,
0.3 mg/kg/day, as reported by Khadilkar et al.) in reducing
ALP levels [8].
Furthermore, we suggest that calcitriol should be the
first line of therapy for rickets in preterm infants instead of
alfacalcidol. Alfacalcidol is 1a-OH-D3, which is an inactive
form of vitamin D that is converted into 1, 25-
dihydroxycholecalciferol (i.e., calcitriol) within the liver
[10]. However, liver functioning in premature infants is
immature, and thereby these patients may have trouble
converting alfacalcidol into 1, 25-dihydroxycholecalciferol.
This notion is supported by Brooke and Lucas [11], who
suggested that alfacalcidol should not be used in the
prevention or treatment of metabolic bone disease in
preterm infants. Another reason for using calcitriol was to
determine its doseeresponse relationship, as there is no
recommended dosage of calcitriol for preterm infants.
The potential side effects of calcitriol include cardiac
arrhythmia, hypertension, hypothermia, sensory
Figure 2. Radiograph of left femur with a rough edge
(arrow).
Premature infants with rickets and calcitriol 455disturbance, hypercalcemia, hyperphosphatemia,
nausea, vomiting, albuminemia, increased creatinine,
and polyuria. Renal function test, such as serum creati-
nine, did not increase in our two cases. Additionally,
elevated liver enzymes are potential adverse reactions of
calcitriol [9]. We observed that g-GT levels were
elevated in both infants, and were reduced with calci-
triol treatment in both cases. It was determined via the
Naranjo algorithm that the initial increase in g-GT levels
was not due to oral calcitriol [12].Table 2 Laboratory data in case 2.
Hospital
day
ALP
60e130 u/L
GOT
18e74 u/L
GPT
(8e78 u/L)
g-GT
(2e30 IU/L)
T
(2
Day 1 25 7
Day 55 1463 180 80 77
Day 57 1095 164 77 83
Day 65 691 274 113 179
Day 72 808 322 245 137
Day 79 862 388 178 76
Day 86 756 254 134 75
Day 103 595 222 169 61
Day 118 613 175 114 87
Day 128 478 211 159 103
ALPZ alkaline phosphatase; CaZ calcium; GOTZ glutamic oxalo
g-GTZ gamma-glutamyl transpeptidase; PZ phosphate.Decreased serum phosphate levels have been shown
to correlate with increased risk of osteopenia and
rickets in premature infants. In one study, six of 24 very
low birth weight (VLBW) infants developed radiological
rickets or severe osteoporosis, and had plasma phos-
phate levels of <3.7 mg/dL, if fed breast milk, or
<5.5 mg/dL, if fed formula milk [13]. Plasma phosphate
levels were 3.75 and 5.0 mg/dL on the same day when
initial ALP levels were measured in cases 1 and 2,
respectively. In these two cases, serum calciumephos-
phorus concentration products were both <40 mg/dL2
(see Tables 1 and 2). Data in our cases support
the conclusion that low plasma phosphate levels may
be a potential risk factor for rickets in premature
infants [13].
Many risk factors of metabolic bone disease have been
previously proposed for preterm infants. Medications
such as corticosteroids, methylxanthines, and diuretics
appear to contribute to the development of metabolic
bone disease in preterm infants [6]. Koo et al. [14]
reported correlations between the presence of skeletal
demineralization and birth weight, gestational age,
enteral feeding, and elevated serum ALP levels. Kovar
et al. [15] suggest that an ALP activity that is five times
higher than the upper limit of the normal adult reference
range is acceptable in preterm infants, but an activity
higher than this may suggest rickets. In addition, the
male sex is also a risk factor of rickets. It is mentioned
that the incidence of rickets is slightly higher in boys for
unknown reasons [2,16]. In both of our cases, we report
on male preterm infants, and thereby corroborate this
observation.
Calcium, phosphate, and magnesium levels should be
monitored periodically when patients are treated with
calcitriol. For example, magnesium does not affect calcium
balance in VLBW or LBW infants, but promotes phosphorus
retention in VLBW infants [17]. Phosphate depletion has
been observed to be accompanied by an increase in urinary
magnesium and calcium [18]. Thus, an adequate magne-
sium level is also important in the daily care of rickets
patients.-bilirubin
e10 mg/dL)
Ca
(8.4e10.2 mg/dL)
P
(4.5e7.5 mg/dL)
Ca P
product
(mg/dL)2
6.2
6.8 7.9 5.0 39.5
6.4
7.1 8.7 2.7 23.49
10.3 9.3 4.7 43.71
14.5
13 9.5 5.8 55.1
10.2 9.7
7.5 9.4
5.5
acetic transaminase; GPTZ glutamic pyruvate transaminase;
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More case studies and data are warranted to determine the
best treatment strategies for preterm infants with rickets.
Based on our experience, we recommend early screening
and mineral supplementation, especially among male
infants who are born with extremely low birth weight (i.e.,
1000 g), are born to mothers with a drug history of
methylxanthines and have low serum phosphate levels.
Furthermore, based on our cases and literature review, we
suggest a 37- to 40-day course of calcitriol (0.1 mg/kg/day)
for the treatment of rickets in preterm infant.
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